Phase 3
Other Related Conditions
Intervention Type
Oral Drug
Funder Type

Drug Details

Nintedanib (Ofev®): Nintedanib is an anti-fibrotic drug that is approved to treat idiopathic pulmonary fibrosis in the United States, Europe, and Australia. In clinical trials, nintedanib has been shown to slow the decline in lung function in mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth twice a day.

Study Purpose
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >